# Ropinirole 0.25 mg Tablets Under Fasting Conditions

> **NCT00829504** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 44 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ropinirole HCl 0.25 mg Tablets
- **DRUG:** Requip® 0.25 mg Tablets

## Key facts

- **NCT ID:** NCT00829504
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2004-10
- **Final completion:** 2004-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2009-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00829504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00829504, "Ropinirole 0.25 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00829504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*